Lough Tony, Luo Qingyang, Luxmanan Carthika, Anderson Alastair, Suttie Jimmy, O'Sullivan Paul, Darling David
Pacific Edge Limited, 87 St David Street, Dunedin, 9016, New Zealand.
University of Otago, Dunedin, New Zealand.
BMC Urol. 2018 Mar 9;18(1):18. doi: 10.1186/s12894-018-0327-6.
The non-invasive Cxbladder urine test system has demonstrated clinical utility in ruling out urothelial carcinoma (UC) in patients with asymptomatic microscopic hematuria (AMH), suggesting that the number of invasive diagnostic tests, including cystoscopy, used in this patient population may be reduced by Cxbladder testing prior to conducting a full urological work-up. The aim of this study was to demonstrate the enhanced clinical utility of communicating objective information on diagnostic decisions made by individual physicians on individual patients with AMH.
Three hundred ninety-six physician-patient decisions were generated from twelve participant physicians evaluating real world case notes from the same 33 patients presenting with AMH. Each physician reviewed and recommended diagnostic tests and procedures based on each patient's referral data and then re-evaluated their clinical recommendation following disclosure of the non-invasive Cxbladder urine test result. Changes assessed were the total number of requested diagnostic procedures and the number of invasive procedures, including cystoscopy, following addition of information from Cxbladder in the Triage and Triage and Detect modalities.
Physicians made significant changes to their diagnostic behavior for patients with AMH when presented with Cxbladder test results, including a reduction in the number of total and invasive procedures including cystoscopy for individuals identified as having a low probability of UC. The intensity of investigation was targeted and increased, including use of total procedures and cystoscopy, for patients identified by Cxbladder tests as having a high probability of UC: urologists increased the level of investigation for both total procedures and invasive procedures. The outcome resulted in patients with a high risk of UC receiving appropriate guideline-recommended invasive diagnostic tests. Patients who tested negative were offered fewer and significantly less invasive procedures. This change in physician behavior results in an increased clinical and patient utility, lower risk of missed UC and invasive test-related harm incidents.
This study demonstrated the potential for increased clinical resolution and significantly enhanced patient management, when physicians consider Cxbladder test results in their clinical evaluation. The change in physician behavior led to more appropriate diagnostic procedure selection and resource allocation to the benefit of both patients and healthcare systems.
无创Cxbladder尿液检测系统已证明在排除无症状镜下血尿(AMH)患者的尿路上皮癌(UC)方面具有临床实用性,这表明在进行全面的泌尿外科检查之前,通过Cxbladder检测可能会减少该患者群体中包括膀胱镜检查在内的侵入性诊断测试的数量。本研究的目的是证明传达个体医生对个体AMH患者做出的诊断决策的客观信息具有更高的临床实用性。
12名参与研究的医生对33例AMH患者的真实病例记录进行评估,共产生了396个医患决策。每位医生根据每位患者的转诊数据审查并推荐诊断测试和程序,然后在披露无创Cxbladder尿液检测结果后重新评估其临床建议。评估的变化包括在分诊和分诊与检测模式中添加Cxbladder信息后,所要求的诊断程序总数和侵入性程序数量,包括膀胱镜检查。
当给出Cxbladder检测结果时,医生对AMH患者的诊断行为发生了显著变化,包括减少了被确定为UC可能性较低的个体的总程序数量和包括膀胱镜检查在内的侵入性程序数量。对于Cxbladder检测确定为UC可能性较高的患者,检查强度有针对性地增加,包括使用总程序和膀胱镜检查:泌尿科医生增加了对总程序和侵入性程序的检查水平。结果是UC高风险患者接受了适当的指南推荐的侵入性诊断测试。检测结果为阴性的患者接受的侵入性程序更少且明显更少。医生行为的这种变化导致临床和患者实用性增加,漏诊UC的风险降低以及侵入性测试相关伤害事件减少。
本研究表明,当医生在临床评估中考虑Cxbladder检测结果时,有可能提高临床分辨率并显著加强患者管理。医生行为的改变导致了更合适的诊断程序选择和资源分配,对患者和医疗系统都有益。